Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Incorporated's 2023 First Quarter Earnings Call. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead.

Thank you very much. Good morning and welcome to Novanta's first quarter 2023 earnings conference call. I am Ray Nash, Corporate Finance Leader of Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. If you've not received a copy of our earnings press release issued today, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note, this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future even if our estimates change. So you should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release. To the extent we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I'm now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.

Thank you, Ray. Good morning, everybody, and thanks for joining our call. Novanta started 2023 with a strong first quarter. In the quarter, we delivered $219 million in revenue, representing 7% year-over-year revenue growth on a reported basis and 8% growth on an organic basis. Our adjusted EBITDA was $47 million, and adjusted diluted earnings per share was $0.74. These results are better than our expectations and guidance, and reflect excellent operating performance by our teams in an evolving macroeconomic environment. We feel the strong performance in the first quarter puts us on track to achieve our full year outlook and it will help drive a more balanced performance in the first half of the year. The Novanta business model, with diversified exposure to high-growth medical and advanced industrial markets, has proven resilient under multiple geopolitical and macroeconomic scenarios. Our proprietary products and technologies are well-positioned in medical and advanced industrial applications with long-term secular tailwinds such as robotics and automation, healthcare productivity, and precision medicine. We feel that the strength of our portfolio and business model, combined with our winning growth strategy, a focus on where we play and how we win, drives our performance no matter the environment. Now let's turn to what we're seeing in our markets and our customer activity. We continue to see strong ongoing demand from our customers in many applications and areas. We made great progress reducing our past due backlog to customers by more than 25% sequentially, while still maintaining a near-record backlog of $604 million, nearly flat with the prior quarter. Our book-to-bill in the first quarter was 0.96, in line with our expectations, and two of our three segments had a book-to-bill greater than 1x in the quarter. As we discussed in the last earnings call, we continue to reduce our lead times for our products back to historical averages and customer expectations. And yet, we continue to see strong demand from customers represented by our strong backlogs, giving us further confidence in our outlook. In the first quarter, sales to medical markets were very robust, growing 22% versus the prior year, making up approximately 54% of total Novanta sales. During the quarter, we saw strong orders and shipments to many of our medical OEM customers with noteworthy strength in minimally invasive surgery equipment and consumables, in vitro diagnostics, patient monitoring equipment, DNA sequencing, and ophthalmology. These categories all saw strong double-digit growth in sales year-over-year. These applications are seeing structural growth based on underlying secular growth drivers such as patient surgical procedure growth rates and advancements in biopharma technologies, including advancements in next-generation DNA sequencing technologies. As we discussed in the fourth quarter earnings call, we continue to expect to see these growth drivers for the remainder of 2023 and in 2024. Turning to the advanced industrial markets, our sales in the quarter, excluding microelectronics applications, were up 1% year-over-year and made up approximately 38% of total Novanta sales. The slower growth was in line with our expectations and is the result of a higher industrial capital spending macro environment, which you can see in macro indicators like the PMI indices. Yet, we continue to see resilient sales performance in many of our industrial end markets, including multiple automation and robotics applications as well as precision manufacturing applications driven by continued underlying demand for factory automation, battery, and electric vehicle production, increased overall adoption of automation and enabling technologies, offset by more GDP-sensitive applications such as engraving and laser cutting. Overall, our industrial exposure is steadily geared towards the secular markets mentioned above. The dynamics in just our microelectronics markets, which represented less than 9% of sales, largely remained unchanged from our last call. We continue to see double-digit declines year-over-year from the cyclical downturn in this market. Consistent with the last quarter, the largest decline manifested in our technology offerings for the PCBA and via-hole drilling equipment market. The overall drop in the microelectronics market remains a 200 to 300 basis point headwind on total Novanta sales growth for the full year. Yet, despite these macro electronic headwinds, Novanta's diversified end market exposure shows the strength of our strategy, enabling the business to grow strongly in the first quarter and still be on track to deliver a solid full-year outlook. From a regional perspective, in the first quarter, sales to North America grew 26% year-over-year, and sales in Europe declined by 1%, reflecting the macroeconomic slowdown this region is working through and its connections with the China market. Sales in China, which represent about 8% of total sales, declined 34% year-over-year, predominantly caused by the decline in microelectronics revenue. Right now, our China exposure is heavily weighted towards these microelectronics applications, but with our ongoing design win activity and focus on high-growth end markets, we expect to better diversify and grow our presence in attractive end markets in the China marketplace in the coming years. Now let me touch on some of Novanta's strategic growth metrics. For the first quarter, our vitality index was about mid-teens percentages of sales, which is down versus the prior year but in line with our expectations. As a reminder, we track new products in the vitality index for the first four years after their production launch. Starting in 2023, several top products, such as our first-generation smoke evacuation products, reached this four-year cutoff milestone, so we're no longer tracking them in the index, although they continue to contribute significantly to our overall sales growth. We expect our vitality index to stay at roughly this mid-teens level for most of 2023, representing a bit of a transition year on this metric. But we do expect this index to rebound in 2024 as we launch and ramp up multiple new product platforms. The investments we've made in our Taunton optics facility, our new Manchester optical subsystem manufacturing facility, and our new Czech Republic medical consumables manufacturing facility are all being done to support this future growth. As such, we also continue to invest heavily in R&D in order to solidify the on-time launch of these platforms. While we have seen some delays in new product launches as a consequence of shifting resources to deal with the microelectronic part shortages over the last two years, we feel confident these milestones will be achieved. Moving on to design wins. For the first quarter, we experienced an expected year-over-year decline which is mainly timing-related. We had a tough year-over-year comparison from large design wins achieved in the first quarter of 2022, mainly in our minimally invasive surgery business associated with our second-generation smoke evacuation insufflators. In this business, we won large new product platforms in 2021 and 2022 with both existing and new customers, which we expect will contribute significantly to our revenue growth in 2025 and beyond. Despite this tough comparison in the first quarter from a percentage growth perspective, we feel good about the absolute wins in dollar terms, and we expect to return to growth in design wins year-over-year as the year progresses. Next, I'd like to give you a brief update on Novanta's acquisition integration activities. Our integration of MPH Medical Devices continues to progress well. The site is ramping up its capabilities to produce Novanta's own proprietary medical consumable products. We successfully implemented a new ERP at the site in the quarter and began ramping production activities to support product qualifications with our customers. And finally, we're changing the names of our three reportable segments: Photonics, Vision, and Precision Motion. We're changing the names of these reportable segments to better reflect our strategic focus and focus on applications. These names also better align with our customers' focus and how our customers see these businesses. The Photonics segment will change its name to Precision Medicine and Manufacturing which more closely fits with the segment's focus on laboratory analytical equipment and technologies, including advancements in next-generation DNA sequencing technologies and on precision manufacturing technologies, including sophisticated laser-based optical subsystems for 3D printing, EUV, micromachining, and e-mobility manufacturing. The Precision Motion segment will change its name to Robotics and Automation, which more closely fits with the segment's focus on industrial and medical robotics technologies, robotic arm technologies, and laboratory automation subsystems. And finally, the Vision segment will change its name to Medical Solutions, which better fits the segment's focus on medical component subsystems and end systems, including smoke evacuation insufflators, endoscopic pumps, integrated operating room technologies, machine vision technologies, and advanced RFID detection technologies, all custom-made for the rigors of an FDA registered medical environment. As a reminder, this segment does not represent all of Novanta's medical end market exposure. In summary, we had a very solid first quarter with excellent sales growth driven by strong demand in medical end markets. We also delivered very healthy operating performance and profit growth, which is based on great progress in deploying the Novanta growth system and continued success at further establishing a thriving company culture. We believe Novanta's long-term strategic positioning continues to be extremely strong and we're staying the course on executing our strategy and capital deployment model. With that, I will turn the call over to Robert to provide more details on our operations and financial performance.

Thank you, Matthijs, and good morning, everyone. The first quarter non-GAAP adjusted gross profit was $101 million or 46% gross margin compared to $94 million or 46% gross margin in the first quarter of 2022. For the quarter, adjusted gross margins were up sequentially over 100 basis points and flat year-over-year. This outcome was better than our expectations and represents strong execution by our teams to achieve this result. This achievement puts us on a solid track to achieving a full-year goal of expanding gross margins by 100 basis points. Moving on to operating expenses; R&D expenses were roughly $23 million or approximately 10% of sales. The first quarter SG&A expenses were $41 million or roughly 19% of sales. Overall, operating expenses as a percent of sales were up sequentially in the quarter as a result of the impact of variable compensation programs and the seasonal payroll taxes, as well as increased R&D investments. Adjusted EBITDA was approximately $47 million in the first quarter of 2023 or 21% adjusted EBITDA margin versus $44 million in the prior year. On the tax front, our non-GAAP tax rate in the first quarter of 2023 was 12%. This differed from the statutory rate due to jurisdictional mix of income and the seasonal impact of equity compensation windfall benefits. Our non-GAAP adjusted earnings per share was $0.74 in the quarter compared to $0.73 in the first quarter of 2022. While adjusted EBITDA grew in the high single-digit range, EPS was muted due solely to higher interest expense. First quarter cash flow was approximately $7 million, which was up 28% versus the prior year. As previously mentioned and communicated, the first quarter typically has lower cash flow due to the timing of incentive compensation payments, equity compensation, vesting events, and the timing of seasonal tax payments. We expect cash flows to continue to improve during the rest of the year as we gradually bring down our inventory to more historical levels and continue to drive strong profitability. We ended the quarter with gross debt of $428 million, and our gross leverage ratio was 2.3x. Our net debt was $345 million, putting the company in a great position to fund further acquisitions. Now, I'll turn to the updated performance of our operating segments. As Matthijs mentioned, we did change the names of our reporting segments in the quarter. We renamed the Photonics segment to Precision Medicine and Manufacturing, our Vision segment is now renamed to Medical Solutions, and our Precision Motion segment is now renamed to Robotics and Automation. I'll start by sharing details about the Precision Medicine and Manufacturing segment, formerly known as Photonics. For the first quarter of 2023, revenue grew 11% year-over-year. This segment continues to experience very strong customer demand in the traditional medical applications and the planned uptick in next-generation DNA sequencing. The book-to-bill in this segment was 1.06 in the quarter, again driven by strong demand in our medical markets and resilient demand from multiple industrial applications focused on productivity-enhancing equipment on the manufacturing floor. In the quarter, bookings in this segment were up 28% and roughly flat year-over-year. The strength in orders puts us in a strong position with good backlog coverage for the remainder of 2023. Within Precision Medicine and Manufacturing, new product revenue stayed strong at greater than 20% of sales in the first quarter. Our sales teams continue to win excellent new business in attractive high-growth medical industrial applications, winning new content, winning new customers, and winning in new applications. Design wins in this segment were down year-over-year, but this was really driven by timing, particularly around the new wins in our intelligent light engine subsystem business branded as Laser Quantum. For the full year, we expect solid design win growth year-over-year. The Precision Medicine and Manufacturing segment adjusted gross margin was 50% in the quarter, which was up nearly 400 basis points year-over-year. This is a great outcome and reflects the efforts and successes this team is having in deploying the Novanta growth system deep into the organization and overcoming some of the operational supply chain challenges they experienced in the prior year. Turning to our Medical Solutions segment, formerly known as Vision; this segment saw reported revenue growth of 25% year-over-year, which was stronger than expectations. Growth in this segment continues to be driven by strength in elective surgical procedures and continued success in our first-generation smoke evacuation insufflator technology, as well as our JADAK business, where the business continues to catch up from past due backlog after supply chain challenges of 2022. The JADAK business is also seeing solid demand in new science and life science equipment applications. The Medical Solutions segment saw a book-to-bill of 1.03 in the first quarter with bookings up 7% sequentially and 12% year-over-year, further indicating the building demand we see in this end market. The vitality index in this segment reduced versus the prior year. As Matthijs mentioned, this is largely driven by first-generation smoke evacuation insufflator products reaching its four-year milestone, and so we are no longer tracking it as part of our official vitality index. As a result, this segment had a vitality index in the mid-teens in the first quarter, which was in line with our expectations. We expect this metric to stay at this level for 2023 but increase thereafter as we launch multiple new second-generation smoke evacuation insufflators which will start to have a significant impact on our sales in the coming years. Design win activity in this segment also declined in the first quarter year-over-year solely from very difficult comparisons from the record-breaking design win progress in 2022 from our second-generation smoke evacuation products. Finally, turning to the Robotics and Automation segment, formerly known as Precision Motion. This segment experienced a revenue decline of 9% year-over-year in the quarter. This was in line with our expectations and prior guidance. This decline continues to be driven by a steep year-over-year decline in microelectronics applications, particularly in the PCBA, via-hole drilling applications, which declined nearly 70%. Excluding this decline, the remainder of the segment grew single digits in the quarter. This decline in PCBA drilling is causing a sales growth headwind for overall Novanta of approximately 200 to 300 basis points in the full year. The overall book-to-bill ratio in this segment was approximately 0.8, again driven by the microelectronics decline in exposure. Microelectronics experienced a negligible level of bookings in the quarter. New product revenue was roughly 10% of sales for this segment in the quarter. This ratio is lower than the prior year because it now includes product sales from our ATI business lines which had minimal new products in its revenue and therefore is having a dampening effect on the overall segment ratio. However, as we mentioned in the fourth quarter, we are working hard on ramping the new product development in this business, and we expect to launch multiple new products in this business in the second half of this year. Adjusted gross margins for the segment came in at $47.5 million, or 47.5%, which was down year-over-year and down sequentially. This is again being driven by the sharp downturn in factory output caused by the decline in the microelectronics market. We expect margins to recover in this segment as the year progresses, both as we manage our cost structure and as other productivity gains gain further traction. Now, turning to guidance. As Matthijs mentioned, we expect to see order behavior from our customers returning to historical patterns as our product lead times drop. Our prior lead times have been as high as 12 months or more, and we are seeing them come down to one-quarter of that level in many cases, which is closer to our historical lead times. We do not see this having any impact on our sales growth outlook for the quarter or for the full year. The strength of our backlog is a reflection of our innovations and the applications in which we participate, with strong demand signals still represented in the larger application areas. From an end market perspective, we see similar dynamics in the second quarter as we did in the first quarter. We expect demand in our medical end markets to remain very strong and we see solid growth coming from our medical capital equipment and medical consumable sales. In our advanced industrial end market, we expect our traditional industrial end markets to stay resilient in the second quarter but with the continued moderation that we saw in the first quarter, in line with the overall macroeconomic and industrial spending environment. We continue to expect our continued disciplined focus on secular growth applications and new product introductions to allow our business to experience growth and weather a more uncertain macroeconomic environment. In our microelectronics end market, we expect continued double-digit declines in the PCBA via-hole drilling applications year-over-year and also some declines in semiconductor wafer fab equipment. As mentioned before, this end application will continue to be a revenue headwind for Novanta in the second quarter in a similar magnitude as we experienced in the first quarter. So starting with revenue guidance; for the second quarter of 2023, we stand here today with GAAP revenue in the range of $222 million to $225 million, which represents revenue growth in the mid-single-digit territory on a year-over-year basis. If you exclude the impact of the microelectronics headwinds, our revenue growth in the second quarter would be low double digits. On a segment level, in the second quarter, we expect the Precision Medicine and Manufacturing segment to grow revenue in the 6% to 8% range on a year-over-year basis. Customer demand remains resilient in this segment with continued growth in multiple medical and industrial applications, including DNA sequencing, ophthalmology, and micromachining. Our Robotics and Automation segment is expected to be flat sequentially and down approximately 10% year-over-year. The year-over-year decline is driven by the downturn in the microelectronics market. Excluding the microelectronics decline, this segment will be growing from demand in industrial robots, medical robots, electric vehicles, and battery production applications. Finally, on Medical Solutions. The segment is expected to demonstrate revenue growth in the 18% to 22% range in the second quarter and is expected to be up sequentially as well. Medical end markets continue to be very strong, driven by a return of elective surgical procedures globally. Moving on to overall Novanta's adjusted gross margin. We expect gross margin in the second quarter to be approximately 46% to 46.5%, which is up sequentially and will continue to demonstrate good expansion year-over-year. The Precision Medicine and Manufacturing segment gross margin is expected to be flat sequentially, whereas the Robotics and Automation segment is expected to be up sequentially. The Medical Solutions segment is expected to see gross margins slightly down sequentially due to a higher mix of medical consumables sales. We believe our team's efforts to use the Novanta growth system will help us sustain and expand gross margins as we progress deeper into the year. Turning to R&D and SG&A expenses. They are expected to be approximately $65 million to $66 million. The increase in cost year-over-year and sequentially is driven by labor cost increases tied to our annual cycle, further investments in innovation, particularly investments in our Medical Solutions segment tied to the aforementioned development of our second-generation smoke evacuation insufflator products, and some further investments in our commercial engine. Depreciation expense, which was about $4 million in the first quarter, will be about the same in the second quarter. Stock compensation expense, which was over $6 million in the first quarter, will be roughly similar in the second quarter. For adjusted EBITDA for the second quarter of 2023, we expect a range of $47 million to $49 million. Interest expense, which was over $6 million in the first quarter, is expected to be about $7 million in the second quarter of 2023, driven by the continued rise in interest rates. We continue to focus on paying down the debt to mitigate the impact of rising rates. We expect our non-GAAP tax rate to be around 18% for the second quarter. The sequential rise in the tax rate from 12% to 18% is driven by our expectations around jurisdictional mix of income as well as timing caused by our first quarter equity compensation windfall benefits. It should be noted that the tax rates across a variety of geographical regions have increased and hence we're working to minimize the impact to Novanta. But clearly, rates will be a little higher than in 2022. Diluted weighted average shares outstanding will be approximately 36 million shares. For adjusted diluted earnings per share, we expect a range of $0.70 to $0.74 in the second quarter. And we expect cash flows to improve sequentially due in part to the seasonal effects mentioned previously and from our continued efforts to bring down our inventory levels. We are also continuing to invest in manufacturing facility expansion projects, such as our new Taunton optics facility, our new Manchester optical subsystem manufacturing facility, and our new Czech Republic medical consumables manufacturing facility. These investments are all critical to support our growth outlook for the next several years. As always, this guidance does not assume any significant changes to foreign exchange rates. In summary, Novanta's performance in the first quarter of 2023 was excellent. We beat our own expectations and the guidance for sales growth, for margins, and for profit performance. We saw tremendous growth in our medical end markets, which more than offset a known headwind in microelectronics. This dynamic is yet another testament of the balance and resiliency of this business portfolio. Our teams continue to deliver great results, helping the company work through a difficult operating environment while still winning new customer platforms and progressing our innovation pipeline. And we continue to see great success at attracting and retaining top talent. Despite a more uncertain macroeconomic environment and the higher interest rate environment, we believe we're on track to achieving our outlook for the full year of 2023 and we see our growth remaining strong well past this year on the back of exciting new product launches starting later this year. We remain very grateful to the outstanding performance of our employees and their tireless efforts to help us be successful in this dynamic environment. We look forward to continuing to deliver on our commitments to our employees, our customers, and our shareholders. This concludes the prepared remarks. We'll now open the call for questions.

And our first question will come from Lee Jagoda of CJS Securities.

So just starting with the microelectronics business. Can you talk about how much of the current run rate today is tied to EUV lithography and how we should think about the growth there? And then sort of secondarily, just comment on the Westwind business? Is this a similar situation to the situation we were in probably 8, 10 years ago where the Westwind business went down close to 0 just because capacity in the space wasn't getting utilized and as capacity gets utilized again, we should expect that business to come back at some point?

Yes. I mean on the last question, you're right. I think there is a tremendous capacity build as a result of the microelectronics boom. And so we'll have to work through that capital utilization, let's say, trough for a little while. And that's why we don't expect that business to come back this year and then microelectronics to stay down for the year. On your first question, we basically in our last call, what we outlined was more of a forward-look view that in, let's say, two years from now, we expect actually the makeup of microelectronics to fundamentally change, more geared towards EUV rather than the exposure to the Westwind business.

So I think we said in the fourth quarter earnings call that we've probably declined to somewhere around 7% of revenue. So overall microelectronics exposure is somewhere close to 8% to 7% of total revenue and the majority of that would be in the EUV deep EUV application area. So as it gets to the end of the year, then we're actually in a territory where we have a secular growing piece of microelectronics.

Okay. That's helpful. And then just on the Czech facility, I think it sounds like you're making some good progress on the qualification of the new products. But just looking at that facility, I think when you bought it, there were some product lines in there that you were trying to get out of there and wind down. Can you give us an update on the progress there and whether that's been a margin headwind or tailwind as a result of the actions you've taken?

It's a great question. Well, probably yes, the effort is to slowly wind that business down. It is a margin headwind. The margins are significantly lower than anything we saw in the company. I would equate it as overall cash neutral because there are some significant qualification costs and then cash outlays associated with bringing our own production up there. And so we're attempting to time that so that as we ramp that business down, it covers the cost of our qualification efforts. That will largely be behind us by the end of the first half. And in the second half, the qualification steps remaining for our production facility rely on the sterilization process. And getting through the final stages there with an expected ramp of production start in the fourth quarter with real volume on a material level starting to come out next year. Now, we've implemented SAP in this site. We've actually started testing some production runs. We've done significant training. We've had equipment moved into the facility. And so overall, we feel we are well on track to ramping up production in medical consumables on our second-generation smoke evacuation products in 2024. And the impact that we're seeing are headwinds on the gross margins associated with the old NPH business will largely be gone by the end of the first half.

Got it. That's helpful. I'll hop back in queue.

The next question comes from Brian Drab of William Blair.

First, on the new product launches. The way that you've been communicating some of the opportunities related to new product launches for 2025, $50 million in revenue opportunity. And I'm wondering if some of the launches that you're talking about coming later this year and in 2024 are opportunities you've had visibility to for some time now? Or are there some new ones? And how do those fit into the context of this 2025 opportunity for $50 million annual revenue that you've been talking about?

I mean, these comments are consistent with that level of $50 million in 2025. And of course, we're ramping also other new product launches but those are consistent with what we've been communicating in our overall growth outlook, right? So we do feel the second half really starts to mark a momentum building up to the levels that you mentioned in 2025, and that's why we made those comments.

One thing, Brian, I'd mention is when you think about why we guided a 2025 number instead of a 2024 number, is that with a lot of these products launching at the end of this year, it means 2024 volumes are going to be harder to predict with a high degree of accuracy because there are different cycles of OEMs coming online at different times throughout the year and different qualifications that they need to engage in with the hospital environment and the medical practitioners. And so as a consequence, we can get very accurate with 2025. In 2024, it will be a larger range and will look funny. So we're being a little bit more cautious on 2024. But all those launches are consistent with that. And I would say that the continued investment in the manufacturing facilities in Manchester and Taunton and in the NPH business are signs of that confidence that we wouldn't be outlaying as much of an investment in those facilities if we didn't believe the growth was on track and materializing in the pace in which we thought it would materialize.

Got it. Okay. So this is not a situation where, at the extreme end, it will be like a bunch of new products or platforms launching at the end of 2024 contributing revenue of $50 million in 2025. It's more of a ramping somewhat in 2024, hitting that run rate in 2025.

Correct.

That's right.

So it reduces the uncertainty around the numbers a bit if you consider it from that viewpoint.

Can you provide more details about the number of opportunities you're discussing? Is there one that represents a larger portion of the $50 million? Any specifics you can share regarding the number of opportunities?

I think we've been consistent in our earnings remarks on this, but let me kind of rephrase it and summarize it. So in the minimally invasive surgery area, we've won many second-generation insufflator businesses, both for endoscopy as well as for robotic surgery markets. And in addition, we've won endoscopic pump business all with multiple OEMs. So that's where the majority of that $50 million is coming from. And then in addition, we see, based on the R&D investments that we've made in other areas such as our beam steering laser beam steering business, for example, our precision business, our Robotics and Automation segment, you see a ramp in new products happening as well in both Robotics and Automation as well as Precision Manufacturing. So electric vehicle, for example, micromachining, EUV, laser additive manufacturing, those are applications that we're primarily targeting with subsystems. And so you see that percentage of the business increasing as well with the launching of new products in those areas. So multiple applications we've talked about and where we're gearing our NPI towards.

Okay. And then just lastly for now. How are you handling pricing lately in this environment? And can you talk at all about how much you expect price to contribute to revenue growth maybe and/or margin expansion in 2023?

I won't go into details, but we have been clear with our customers that the price increase is helping to counteract the inflationary pressures we are experiencing, and that this is part of our sharing arrangement. This is the message we have communicated to our customers and externally, and it reflects the efforts we have made. It is important to note that in 2023, there is a noticeable division where material costs or capital goods are showing some potential for cost reductions, though microelectronics might be an exception in certain areas. Meanwhile, services, third-party services, utilities, and other support services are still facing inflation. Therefore, we anticipate inflation to be a challenge in 2023, and we see price as a way to mitigate that impact. Ultimately, our goal is to increase gross margins by 100 basis points, which we expect to achieve by introducing new products and implementing the Novanta growth system in our operations. We are confident in this approach. We achieved a solid gross margin in the first quarter and anticipate maintaining that in the second quarter, continuing our progress throughout the year to reach our 100 basis point goal.

Got it.

You had mentioned that you made some good progress reducing your past dues on the backlog. I'm just curious what percent of your backlog now is in that past due category?

Yes, I don't think we've shared that information, but reducing our past due backlog by 25% sequentially is very significant. More importantly, we've decreased lead times for our customers from sometimes over a year to now less than 12 weeks, and in some cases, even under 6 weeks. This represents a dramatic reduction in lead times due to the strong efforts of our operations teams. We are pleased with our progress in catching up to the demand our customers expect from us. Essentially, we are starting to substantially catch up. Lead times are returning to pre-pandemic historical averages. Additionally, our backlog as a percentage of expected revenue for the next 12 months remains in record territory at mid- to high 60s percentages, compared to historical levels of around mid-30s percentages. So, while we still have a historically high backlog, the past due items are decreasing quickly, and lead times are also improving rapidly.

Matthijs, would you expect that backlog percentage eventually on next 12 months' revenue to work towards that historical level? Or is there anything structurally different in the way that your customers are going to order or that you would view your backlog?

It's a bit difficult to predict, but we anticipate that the mid-60s is unusually high and should decrease. Our customers typically don't need to place orders for a full year when we have lead times of six weeks, which has been the historical norm. Previously, our book-to-bill ratio averaged about 1, and we expect that to return to those levels over time. However, before that can happen, we need to reduce the backlog and fulfill orders for our customers. I do believe it will decrease closer to historical levels, though it might remain slightly elevated compared to the past. It's challenging to be certain, though.

Yes. Looking back at the fourth quarter, I provided some rough guidance on this. We will not return to a situation where there is only a quarter's worth of backlog, but we also won't remain at the current levels. I hope that by the end of the second quarter, we will have managed our past due issues, assuming everything goes as planned. At that point, we will only have marginal past due levels. What we are facing is a significant demand for future orders as companies prepare for production increases of new products in 2024 and beyond. Consequently, we will maintain an elevated backlog due to this demand. Many new products are coming online, resulting in levels that will be higher than historical averages, but still below what contributed to the past due problems.

I understand. You mentioned some of your second-generation products being released. It seems likely that you have gained some new customers and OEMs. Considering the growth in this area, do you think it is driven more by acquiring new customers or by increasing content from existing ones?

It's a great question. It's a combination. We believe our second-generation smoke evacuation insufflator technology will become a standard of care, meaning it will be standard in all minimally invasive surgical procedures moving forward. It takes time to achieve significant penetration in the global market for that. We make this comment largely because we've gained new customers, entered new application areas, and replaced older technologies we had previously. We've done a mix of things. The first-generation product was launched with a single large customer, which was relatively limited. In the future, you'll see a wider distribution of our new offering being sold to many customers, including some we haven't served before.

Just to clarify regarding the microelectronics business, it seems that this segment is expected to have flat revenue for the rest of the year. Is that accurate? Do you believe it has stabilized?

Yes, that's correct. We expect the revenue to remain relatively flat for the full year. The percentages may decline as we face easier comparisons in the second half of the year. However, there are underlying dynamics at play. We're seeing growth in EUV and deep EUV, while some areas, particularly in back-end semiconductor equipment, are experiencing weaknesses. As we move out of 2023, we anticipate being largely in a growth category, and we expect that growth to continue in 2024 as we increase our content and penetration in EUV applications.

Got it. Thank you.

This will conclude our question-and-answer session. I would like to turn the conference back over to Mr. Matthijs Glastra for any closing remarks.

Thank you, operator. And so to recap, Novanta had a very impressive first quarter 2023. We saw good sales growth despite the headwinds that we mentioned in microelectronics and beat our own expectations for margins and profit. We've maintained a very robust level of backlog while reducing our lead times and our past due backlog, and we continue to see strong tailwinds in our medical businesses. We're progressing our innovation pipeline, and we're excited for the large product launches happening later this year and next year. We feel we're on track with our full year 2023 outlook. Novanta remains well positioned in the medical and advanced industrial end markets with diversified exposure to long-term secular market trends in robotics and automation, precision medicine, minimally invasive surgery, and Industry 4.0. In 2023 and beyond, we will continue to focus on new product development, design wins, and high-growth applications, driving cash flows and institutionalizing the Novanta growth system. In closing, as always, I would like to thank our customers and our employees and our shareholders for their ongoing support. I continue to be especially grateful for the dedicated efforts of all our Novanta teammates who work diligently every day to tackle new opportunities and manage through new challenges. We appreciate your interest in the company and your participation in today's call. I look forward to joining all of you in several months on our second quarter 2023 earnings call. Thank you very much. This call is now adjourned.

The conference has now concluded. Thank you for attending today's presentation, and you may now disconnect.